CD274 and neoplasm: Among 28 patients in the response and survival analysis, tumor tissues were available from 23 (82.1%) for PD-L1 expression assessment by JS311, including 3 (13.0%) with TPS of at least 50%, 2 (8.7%) with TPS of 1% to 49%, and 18 (78.3%) with TPS of less than 1%.